Literature DB >> 23798540

Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria.

Paula M Chilton1, Diana M Hadel, Thao T To, Thomas C Mitchell, Richard P Darveau.   

Abstract

Natural heterogeneity in the structure of the lipid A portion of lipopolysaccharide (LPS) produces differential effects on the innate immune response. Gram-negative bacterial species produce LPS structures that differ from the classic endotoxic LPS structures. These differences include hypoacylation and hypophosphorylation of the diglucosamine backbone, both differences known to decrease LPS toxicity. The effect of decreased toxicity on the adjuvant properties of many of these LPS structures has not been fully explored. Here we demonstrate that two naturally produced forms of monophosphorylated LPS, from the mucosa-associated bacteria Bacteroides thetaiotaomicron and Prevotella intermedia, function as immunological adjuvants for antigen-specific immune responses. Each form of mucosal LPS increased vaccination-initiated antigen-specific antibody titers in both quantity and quality when given simultaneously with vaccine antigen preparations. Interestingly, adjuvant effects on initial T cell clonal expansion were selective for CD4 T cells. No significant increase in CD8 T cell expansion was detected. MyD88/Toll-like receptor 4 (TLR4) and TRIF/TLR4 signaling pathways showed equally decreased signaling with the LPS forms studied here as with endotoxic LPS or detoxified monophosphorylated lipid A (MPLA). Natural monophosphorylated LPS from mucosa-associated bacteria functions as a weak but effective adjuvant for specific immune responses, with preferential effects on antibody and CD4 T cell responses over CD8 T cell responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798540      PMCID: PMC3754217          DOI: 10.1128/IAI.01150-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  The lipid A phosphate position determines differential host Toll-like receptor 4 responses to phylogenetically related symbiotic and pathogenic bacteria.

Authors:  Stephen R Coats; Alex B Berezow; Thao T To; Sumita Jain; Brian W Bainbridge; Karim P Banani; Richard P Darveau
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.

Authors:  M Rosewich; J Schulze; O Eickmeier; T Telles; M A Rose; R Schubert; S Zielen
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

3.  Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.

Authors:  Eszter Deak; Asha Jayakumar; Ka Wing Cho; Karen Goldsmith-Pestana; Blaise Dondji; John D Lambris; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

4.  Pathological role of Toll-like receptor signaling in cerebral malaria.

Authors:  Cevayir Coban; Ken J Ishii; Satoshi Uematsu; Nobuko Arisue; Shintaro Sato; Masahiro Yamamoto; Taro Kawai; Osamu Takeuchi; Hajime Hisaeda; Toshihiro Horii; Shizuo Akira
Journal:  Int Immunol       Date:  2006-11-29       Impact factor: 4.823

5.  Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.

Authors:  Chelsea A Embry; Luigi Franchi; Gabriel Nuñez; Thomas C Mitchell
Journal:  Sci Signal       Date:  2011-05-03       Impact factor: 8.192

6.  Hemin-dependent modulation of the lipid A structure of Porphyromonas gingivalis lipopolysaccharide.

Authors:  Montaser N Al-Qutub; Pamela H Braham; Lisa M Karimi-Naser; Xinyan Liu; Caroline A Genco; Richard P Darveau
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

7.  A deficiency in the B cell response of C57BL/6 mice correlates with loss of macrophage-mediated killing of Leishmania amazonensis.

Authors:  Katherine N Gibson-Corley; Paola M Boggiatto; Rami M Mukbel; Christine A Petersen; Douglas E Jones
Journal:  Int J Parasitol       Date:  2009-12-11       Impact factor: 3.981

8.  Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.

Authors:  Caglar Cekic; Carolyn R Casella; Chelsea A Eaves; Atsushi Matsuzawa; Hidenori Ichijo; Thomas C Mitchell
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

9.  Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.

Authors:  William S Bowen; Laurie A Minns; David A Johnson; Thomas C Mitchell; Melinda M Hutton; Jay T Evans
Journal:  Sci Signal       Date:  2012-02-14       Impact factor: 8.192

10.  Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Authors:  Rhea N Coler; Sylvie Bertholet; Magdalini Moutaftsi; Jeff A Guderian; Hillarie Plessner Windish; Susan L Baldwin; Elsa M Laughlin; Malcolm S Duthie; Christopher B Fox; Darrick Carter; Martin Friede; Thomas S Vedvick; Steven G Reed
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

View more
  13 in total

1.  Bordetella pertussis Lipid A Recognition by Toll-like Receptor 4 and MD-2 Is Dependent on Distinct Charged and Uncharged Interfaces.

Authors:  Nina Maeshima; Tara Evans-Atkinson; Adeline M Hajjar; Rachel C Fernandez
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

2.  Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies.

Authors:  Wei Zhang; Seong-Min Lim; Juyoung Hwang; Srinivasan Ramalingam; Myunghee Kim; Jun-O Jin
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

Review 3.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13

Review 4.  Like Cures Like: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides From Gut Microbiome.

Authors:  Tzu-Lung Lin; Chin-Chung Shu; Young-Mao Chen; Jang-Jih Lu; Ting-Shu Wu; Wei-Fan Lai; Chi-Meng Tzeng; Hsin-Chih Lai; Chia-Chen Lu
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

5.  Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis.

Authors:  Marlies Schippers; Eduard Post; Ilse Eichhorn; Jitske Langeland; Leonie Beljaars; Madhu S Malo; Richard A Hodin; José Luis Millán; Yury Popov; Detlef Schuppan; Klaas Poelstra
Journal:  Cells       Date:  2020-12-17       Impact factor: 6.600

Review 6.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

7.  Surfactin inducing mitochondria-dependent ROS to activate MAPKs, NF-κB and inflammasomes in macrophages for adjuvant activity.

Authors:  Ping Gan; Zhenqiu Gao; Xiuyun Zhao; Gaofu Qi
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

Review 8.  Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors.

Authors:  Nobuo Fuke; Naoto Nagata; Hiroyuki Suganuma; Tsuguhito Ota
Journal:  Nutrients       Date:  2019-09-23       Impact factor: 5.717

9.  Links between fecal microbiota and the response to vaccination against influenza A virus in pigs.

Authors:  Marion Borey; Fany Blanc; Gaëtan Lemonnier; Jean-Jacques Leplat; Deborah Jardet; Marie-Noëlle Rossignol; Laure Ravon; Yvon Billon; Maria Bernard; Jordi Estellé; Claire Rogel-Gaillard
Journal:  NPJ Vaccines       Date:  2021-07-22       Impact factor: 7.344

Review 10.  From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants.

Authors:  Adélia Mendes; João Azevedo-Silva; João C Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.